Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML

Published:2020-03-05 Issue:10 Volume:135 Page:766-769
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gottschalk Andrea¹^ORCID,Glauche Ingmar¹^ORCID,Cicconi Silvia²^ORCID,Clark Richard E.³^ORCID,Roeder Ingo¹⁴^ORCID

Affiliation:

1. Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany;

2. Department of Molecular and Clinical Cancer Medicine and

3. Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; and

4. National Center for Tumor Diseases, Partner Site Dresden, Dresden, Germany

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/10/766/1717878/bloodbld2019003395.pdf

Reference11 articles.

1. Chronic myeloid leukaemia;Apperley;Lancet,2015

2. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring;Jabbour;Am J Hematol,2016

3. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol,2016

4. Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response;Cervantes;Ann Hematol,2017

5. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data;Fassoni;Haematologica,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?;British Journal of Haematology;2023-12-26

3. Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia;Cancer Medicine;2023-07-06

4. Data integration between clinical research and patient care: A framework for context-depending data sharing and in silico predictions;PLOS Digital Health;2023-05-15

5. A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia;Pharmaceutics;2023-04-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3